REPRO-MED Systems (KRMD) AI Stock Analysis

• Market Cap: $178.47M
• Dividend Yield: N/A
• Average Volume (3M): 91.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 19.57%
• EPS Growth: 61.81%
• Country: US
• Employees: 80
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.02
• Shares Outstanding: 46,234,960
• 10 Day Avg. Volume: 54,917
• 30 Day Avg. Volume: 91,822
• PEG Ratio: 0.51
• Price to Book (P/B): 10.49
• Price to Sales (P/S): 5.24
• P/FCF Ratio: -109.04
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 4.36
• Enterprise Value/Gross Profit: 6.91
• Enterprise Value/Ebitda: -42.68
• 1Y Price Target: $5.00
• Price Target Upside: 20.77% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $4.00 ▼(-3.38% Downside)

The overall score reflects significant challenges in profitability and valuation, despite positive revenue growth and international expansion. Technical indicators show mixed signals, and while the earnings call was optimistic, concerns about margins and domestic revenue impact remain.

Positive Factors

International Expansion

Strong international growth indicates successful market penetration and diversification, reducing dependency on domestic markets and enhancing long-term revenue stability.

Product Development

Advancements in product development, including next-gen pump and flow controller, position the company for future growth and competitiveness in the medical device market.

Revenue Growth

Significant revenue growth reflects strong demand for products and effective sales strategies, supporting long-term financial health and market position.

Negative Factors

Profitability Challenges

Ongoing profitability issues, with negative margins, could hinder the company's ability to reinvest and grow, impacting long-term financial sustainability.

Gross Margin Decline

Declining gross margins due to external factors like tariffs may pressure profitability, requiring strategic cost management to maintain financial performance.

Cash Flow Concerns

Negative cash flows indicate potential liquidity issues, limiting the company's ability to fund operations and growth initiatives without external financing.

REPRO-MED Systems Business Overview & Revenue Model

Company Description

REPRO-MED Systems, Inc. (KRMD) is a medical technology company specializing in the development and manufacturing of innovative medical devices and solutions for the healthcare sector. The company focuses primarily on the area of infusion therapy, providing products that improve the delivery of medications to patients with chronic conditions. Its core products include the proprietary infusion pump system, the FREEDOM60, designed for subcutaneous drug delivery, and other related accessories. REPRO-MED Systems operates in the medical device sector, targeting patients requiring home healthcare solutions, as well as healthcare providers and institutions.

How the Company Makes Money

REPRO-MED Systems generates revenue through the sale of its medical devices, primarily the FREEDOM60 infusion system and its associated accessories. The company's revenue model is based on direct sales to healthcare providers, distributors, and patients, as well as potential recurring revenue from consumable products related to its infusion systems. Key revenue streams include the initial sale of infusion pumps and ongoing sales of disposable components that require regular replacement. Additionally, partnerships with healthcare organizations and networks can enhance distribution capabilities and broaden market access, contributing to the company's overall earnings.

REPRO-MED Systems Financial Statement Overview

Summary

REPRO-MED Systems shows modest revenue growth but struggles with profitability and cash flow. The balance sheet is stable with low leverage, but operational inefficiencies hinder financial health.

Income Statement

REPRO-MED Systems shows a modest revenue growth rate of 5.03% TTM, indicating some positive momentum. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains relatively stable, suggesting efficient cost management at the production level, but overall profitability is hindered by high operating expenses.

Balance Sheet

The company's debt-to-equity ratio is manageable at 0.21, indicating a conservative leverage strategy. However, the return on equity is negative, reflecting ongoing losses and challenges in generating shareholder value. The equity ratio is not explicitly calculated, but the balance sheet shows a reasonable level of equity relative to assets.

Cash Flow

The cash flow statement reveals negative operating and free cash flows, which are concerning for liquidity. Despite a positive free cash flow growth rate, the company is still generating insufficient cash to cover its net income, as shown by the high free cash flow to net income ratio. This indicates potential cash flow management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.85M	33.65M	28.52M	27.90M	23.49M	24.18M
Gross Profit	23.27M	21.33M	16.71M	15.37M	13.77M	14.94M
EBITDA	-3.77M	-5.56M	-9.40M	-10.19M	-6.57M	1.61M
Net Income	-4.52M	-6.07M	-13.74M	-8.66M	-4.56M	-1.21M
Balance Sheet
Total Assets	25.52M	27.22M	28.46M	42.33M	41.29M	39.92M
Cash, Cash Equivalents and Short-Term Investments	8.05M	9.58M	11.48M	17.41M	25.33M	27.32M
Total Debt	3.47M	3.99M	4.45M	4.93M	604.14K	239.49K
Total Liabilities	8.99M	10.40M	8.11M	11.01M	4.79M	3.76M
Stockholders Equity	16.53M	16.81M	20.35M	31.33M	36.50M	36.16M
Cash Flow
Free Cash Flow	-2.17M	-1.62M	-5.71M	-8.21M	-4.69M	-1.80M
Operating Cash Flow	-682.14K	-319.72K	-4.89M	-5.40M	-4.32M	-743.32K
Investing Cash Flow	-1.53M	-1.33M	-814.60K	-2.80M	-366.17K	-1.04M
Financing Cash Flow	-194.03K	-248.53K	-218.87K	279.49K	2.71M	23.22M

REPRO-MED Systems Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRMD, the sentiment is Negative. The current price of 4.14 is above the 20-day moving average (MA) of 4.01, above the 50-day MA of 4.01, and above the 200-day MA of 3.50, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 40.44 is Neutral, neither overbought nor oversold. The STOCH value of 24.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KRMD.

REPRO-MED Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	68 Neutral	$193.23M	39.88	9.95%	―	6.23%	283.88%
UTMD	63 Neutral	$183.62M	16.21	9.59%	2.09%	-12.35%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KRMD	50 Neutral	$178.47M	-39.27	-25.63%	―	19.57%	61.81%
OSUR	44 Neutral	$167.14M	―	-15.30%	―	-43.95%	-620.21%

REPRO-MED Systems Corporate Events

KORU Medical Systems Reports Strong Q2 2025 Growth

KORU Medical Systems’ recent earnings call painted a picture of robust growth and strategic advancements, tempered by some operational challenges. The company reported significant revenue growth and international expansion, alongside advancements in product development and achieving positive cash flow. However, concerns were raised regarding a decline in gross margin and anticipated domestic inventory reductions.

KORU Medical Systems Reports Record Q2 2025 Results

KORU Medical Systems, Inc., a prominent player in the medical technology sector, specializes in developing, manufacturing, and commercializing large volume subcutaneous infusion solutions aimed at enhancing patient quality of life.